Quick Answer
AEON Biopharma, Inc. reported Total Assets of $5.56 million for the year ending 2025.
- AEON Biopharma, Inc. showed an increase of +77.0% in Total Assets from 2024 to 2025.
- This data is from AEON Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $278.15 million | Q2 2021: $277.62 million | Q3 2021: $277.20 million | Q1 2022: $276.65 million | Q2 2022: $276.51 million | Q3 2022: $277.32 million | Q1 2023: $21.62 million | Q2 2023: $21.79 million | Q3 2023: $17.62 million | Q1 2024: $3.03 million | Q2 2024: $5.73 million | Q3 2024: $4.00 million | Q1 2025: $13.80 million | Q2 2025: $11.66 million | Q3 2025: $8.73 million.
- Over the full 6 years of available data (2020 to 2025), AEON Biopharma, Inc.'s Total Assets has grown by 6,764.2%.
- Historical annual values: Fiscal year 2025: $5.56 million | Fiscal year 2024: $3.14 million | Fiscal year 2023: $6.85 million | Fiscal year 2022: $10.78 million | Fiscal year 2021: $276.95 million | Fiscal year 2020: $81.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: